Healthcare Today Montana
SEE OTHER BRANDS

News on health and wellness in Montana

Healthcare Today Montana: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Today Montana.

Press releases published on August 13, 2025

Milestone Scientific Schedules Second Quarter 2025 Financial Results and Business Update Conference Call

Milestone Scientific Schedules Second Quarter 2025 Financial Results and Business Update Conference Call

ROSELAND, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8: …

Erdem Hospital Performs First-of-Its-Kind Spinal Revision Surgery

Erdem Hospital Performs First-of-Its-Kind Spinal Revision Surgery

Photo: Erdem Hospital via FL Communications ISTANBUL, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Erdem Hospital has announced the successful completion of a first-of-its-kind spinal revision surgery, restoring mobility to a 50-year-old Italian patient after years …

Muscular Endurance: Bodybuilders Choose CrazyBulk Bodybuilding Supplements For Peak Performance & Strength Building

Muscular Endurance: Bodybuilders Choose CrazyBulk Bodybuilding Supplements For Peak Performance & Strength Building

In competitive bodybuilding, muscular endurance can be the deciding factor between finishing strong or hitting an early wall. While strength defines how much weight you can lift, endurance determines how long you can sustain intense training without …

Grady Health System Named Recipient of Scholarship Program from Joint Commission and the National Association for Healthcare Quality

Grady Health System Named Recipient of Scholarship Program from Joint Commission and the National Association for Healthcare Quality

OAKBROOK TERRACE, Illinois, Aug. 13, 2025 (GLOBE NEWSWIRE) -- As part of the strategic alliance between Joint Commission and the National Association for Healthcare Quality (NAHQ) to improve global healthcare, the organizations announce today the …

Jackson Health System Health Named Recipient of Scholarship Program from Joint Commission and the National Association for Healthcare Quality

Jackson Health System Health Named Recipient of Scholarship Program from Joint Commission and the National Association for Healthcare Quality

OAKBROOK TERRACE, Illinois, Aug. 13, 2025 (GLOBE NEWSWIRE) -- As part of the strategic alliance between Joint Commission and the National Association for Healthcare Quality (NAHQ) to improve global healthcare, the organizations announce today the …

Cook County Health Named Recipient of Scholarship Program from Joint Commission and the National Association for Healthcare Quality

Cook County Health Named Recipient of Scholarship Program from Joint Commission and the National Association for Healthcare Quality

OAKBROOK TERRACE, Illinois, Aug. 13, 2025 (GLOBE NEWSWIRE) -- As part of the strategic alliance between Joint Commission and the National Association for Healthcare Quality (NAHQ) to improve global healthcare, the organizations announce today the …

Natural Weight Loss Supplements: How PhenQ Became the Leading Alternative to Anti-Obesity Injections in 2025

Natural Weight Loss Supplements: How PhenQ Became the Leading Alternative to Anti-Obesity Injections in 2025

London, UK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- PhenQ leads 2025 with a multi-action, science-informed approach to weight loss - no needles, no prescriptions, just clean, sustainable natural weight management that fits real life. In 2025, the conversation …

National Healthcareer Association Launches New Membership Community Platform

National Healthcareer Association Launches New Membership Community Platform

LEAWOOD, Kan., Aug. 13, 2025 (GLOBE NEWSWIRE) -- The National Healthcareer Association (NHA), the largest allied health certification agency in the United States, today announced the launch of its NHA Membership Program Community platform, an initiative …

Positron Corporation Secures Multi-Unit Sale of PET-CT Scanners to Leading Cardiology Group

Positron Corporation Secures Multi-Unit Sale of PET-CT Scanners to Leading Cardiology Group

Niagara Falls, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leader in molecular imaging technology and services, today announced the sale of four (4) PET-CT 64-slice scanners to a nationally …

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that the U.S. Food and Drug Administration ( …

MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy

MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy

Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells  CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical …

ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones

ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones

KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) was activated June 2025; patient screening is underway, with interim results expected ~Q4-2025. IND- …

Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track for Q4 2025 - - Low discontinuation rate (5.8%) due to adverse …

Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

– Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations – – Presented positive data at ATS 2025 and EAACI 2025 supporting the potential of rademikibart to deliver differentiated …

24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy

24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy

DENVER, Aug. 13, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that LIXTE Biotechnology Holdings (Nasdaq: LIXT), a clinical-stage …

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers Post hoc analysis published in Advances in Wound Care, provides clinical evidence supporting wound bed …

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept demonstrated a favorable safety profile Vor evaluating timing of global Phase 3 clinical study in primary Sjögren's disease Data …

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases …

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

- Continues recruitment and opens US and EU sites for the Phase 2B/3 MIRACLE trial - 20+ additional clinical sites in Europe and the US expected to begin recruitment by the end of Q3 - Anticipated data readout of MIRACLE Part A targeted before end of 2025 …

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

COMMACK, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions